NEO

NeoGenomics, Inc.

$16.42

-1.38% 2026-10-19

Health CareS&P 600

1M 3M 6M 1Y 2Y

NEOSPY

+1.4%

-17.5%

+15.3%

+99.5%

YTD

+39.6%

+63.4%

Grades vs sector

Momentum

95th pct in sector

A+

12-1 return: +87.9%
Percentile within its GICS sector across the S&P 1500.

Growth

64th pct in sector

B-

Revenue growth (YoY): +11.2%
Percentile within its GICS sector across the S&P 1500.

Value

4th pct in sector

Forward E/P: 2.1% · EBITDA/EV: 1.0%
Percentile within its GICS sector across the S&P 1500.

Profitability

15th pct in sector

D-

Profit margin: -6.8% · Return on equity: -6.3%
Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Held by 1 of 3 live models: Momentum Blend.

Momentum Blend

5.4% of the book · Leaders sleeve

Held Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Why it's in Momentum Blend

In the Leaders sleeve: a fast grower breaking out near its highs after an earnings-style gap.

What would knock it out: Exits if it closes below its stop of $14.56; last close $16.42, 13% above it.

Key stats

Market cap$2.1B

P/E (trailing)–

P/E (forward)47.9

52-week range7.07 – 20.15

Revenue growth (YoY, latest qtr)+11.2%

Dividend yield0.00%

Analyst consensusBuy (10)

Mean price target$21.85 (+33%)

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

▼Forward P/E vs sector47.9x vs median 17.6x

•Piotroski F-score4/9

•Altman Z2.4 (grey)

▲Analyst target+33% (10 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.78 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6× · 94th pct

47.9×
pricier

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1× · 46th pct

2.8×
cheaper

Price / book

sector median 3.5× · 38th pct

2.7×
cheaper

FCF yield

sector median 4.1% · 10th pct

-0.3%
pricier

Forward EPS $0.34 vs trailing $-0.39. Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$267.0M

as of 2021-12-31

vs a year ago

+28%

YoY

× TTM revenue

0.35×

coverage

18-03

18-06

18-09

18-12

19-12

20-12

21-12

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

43.9%

Operating margin

-8.9%

FCF margin

-1.0%

Net margin

-6.8%

Return on equity

-6.6%

Return on invested capital

-6.5%

Net debt / EBITDA

–

Current ratio

3.6×

Interest cover

-26.5×

Cash conversion (OCF/NI)

–

Piotroski F-score 4/9 · last two fiscal years

✗ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 2.4 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$22

+33%

Analysts

Buy

Range

$16–$35

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$727.3M	$-108.0M	$-21.8M
2024	$660.6M	$-78.7M	$-34.0M
2023	$591.6M	$-88.0M	$-30.7M
2022	$509.7M	$-144.2M	$-96.9M
2021	$484.3M	$-8.3M	$-90.9M
2020	$444.4M	$4.2M	$-27.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +12.6%.

Earnings

Next report: 2026-10-28 · after close · EPS est 0.06

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-28	0.03	0.05	+48.6%
2026-04-28	–	0.01	+800.9%
2026-02-17	0.04	0.06	+50.0%
2025-10-28	0.02	0.03	+25.8%
2025-07-29	0.02	0.03	+21.9%
2025-02-18	0.03	0.04	+40.0%
2024-11-05	0.01	0.05	+500.2%
2024-07-29	–	0.03	+1398.7%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$201.7M	+11.2%
2026-03-31	$186.7M	–
2025-12-31	$190.2M	–
2025-09-30	$187.8M	–
2025-06-30	$181.3M	–

Analyst actions

StoneX

2026-10-06 · main

Buy → Buy
PT $20

Needham

2026-10-06 · main

Buy → Buy
PT $22

BTIG

2026-10-06 · up

Neutral → Buy
PT $28

Needham

2026-07-29 · main

Buy → Buy
PT $19

Benchmark

2026-07-24 · main

Buy → Buy
PT $16

Benchmark

2026-04-29 · up

Hold → Buy
PT $11

Insider trades

Aunan Greg D

Chief Accounting Officer · 2026-08-04

SELL
$321.4K

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

News

JinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency

PR Newswire · Oct 17

Havila Shipping ASA: 3-years contracts with Neo Next + UK for the PSVs Havila Fanø and Havila Herøy

GlobeNewswire · Oct 16

Syntiant Brings Always-On Physical AI to STEPX Neo Agentic Phone

GlobeNewswire · Oct 15

NeoGenomics Expands AI-Driven Digital Pathology Capabilities

MT Newswires · Oct 15

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

Business Wire · Oct 15

Joe Magdovitz Joins AI Neo-Insurer MGT as Head of Finance

Business Wire · Oct 14

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

Business Wire · Oct 14

Neo Performance Materials' Rare Earth Facility Modernization Selected as EU Strategic Project

MT Newswires · Oct 14

Stats refreshed 2026-10-19 17:47:05 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status